Computer Vision News - October 2019

Lina Kontos 15 They probably see that there is a lot of value that is being added by new technologies and ways to include them in their considerations. Is that right? Yes, absolutely. There is always room for more innovation. There is a lot of innovation in the AI/ML area right now, as I am sure your readers are well aware. So far, we’ve mostly seen activity in engaging with FDA in the area of diagnostics, where it has either been some sort of computer- aided detection or a triaging system. We all know there is lots going on in other areas, so I am looking forward to working with companies where we get into more therapeutic issues as well. FDA in the area of diagnostics, where it has either been some sort of computer-aided detection or a triaging system. We all know there is lots going on in other areas, so I am looking forward to working with companies where we get into more therapeutic issues as well. FDA is still figuring out exactly how far to go with the adaptive technologies in these areas. Right now, it is still very much locked configurations that are getting cleared with minor changes allowed following those clearances according to set protocols that FDA reviews. The more significant changes impact the indications for use of the device or really evolve the device further into doing more or being able to see more still require another touch with FDA to get another clearance. What kindof companies shouldbe in touch with you to do business? In my group, we mostly work with medical device companies. Obviously, we are a huge international law firm. We do a little bit of everything. We have 2,500 attorneys worldwide. If there are other needs, we certainly can find someone to help. For me, personally, it is medical device companies or " I love working in the medi cal dev i ce arena"